Trimetazidina en el tratamiento del angor estable

Álvaro Danza; Federico Cristiani; Gustavo Tamosiunas

Álvaro Danza Universidad de la República, Facultad de Medicina, Departamento de Farmacología y Terapéutica. Departamento Clínico de Medicina. Farmacología y Terapéutica, Asistente. Clínica Médica "A", Ex Residente
Federico Cristiani Universidad de la República, Facultad de Medicina, Departamento de Farmacología y Terapéutica, Farmacología y Terapéutica, Ayudante. Practicante Interno
Gustavo Tamosiunas Universidad de la República, Facultad de Medicina, Farmacología y Terapéutica. Departamento de Farmacología y Terapéutica, Profesor Agregado. Especialista en Cardiología y en Farmacología y Terapéutica

Keywords: ANGINA PECTORIS, TRIMETAZIDINE, DRUG EVALUATION

Abstract

Introduction: ischaemic cardipathy is a highly prevalent disease in our country. It is caused by an imbalance between the oxygen requirement of the myocardium and the oxygen supplied to it. Conventional therapeutics focuses on modification of hemodynamics variables. However, a significant number of patients still evidenced symptoms after applying these therapeutics. Thus, new ways of drug (non-hemodynamic) interventions are being sought, such as metabolic kinds of intervention, by increasing myocardial energy substrates yield. Trimetazidine is a drug that acts by modulating myocardial metabolism, proving to be a new and promising action mechanism.
Objective: to update and perform a critical analysis of the information on the efficacy and safety of trimetazidine in treating stable angina pectoris that is currently available, thus learning about its usefulness in clinical practice and encouraging its rational use.
Method: Medline, Lilacs and Cochrane Databases were searched, looking for information. To learn about its efficacy, controlled clinical trials, systematic reviews and meta-analysis were included. To learn about safety, notifications, series of cases and drug surveillance bulletins were also integrated.
Results: studies conducted showed symptomatic improvement with trimetazidine, with no notifications of serious adverse effects, although elderly patients evidenced extrapyramidal symptoms.
Conclusions: trimetazidine has been shown to improve symptoms in patients with stable angina pectoris. There is no information about its effects on "hard" variables such as mortality or myocardial infarction. As with all new drugs, active safety surveillance is advised.

References

(1) Comisión Honoraria para la Salud Cardiovascular. Informe resumen de mortalidad y morbilidad por enfermedades Cardiovasculares en el Uruguay. (2003/2004). Montevideo: Comisión Honoraria para la Salud Cardiovascular, 2006: 6 p.
(2) Goswami NJ, O’Rourke RA. Pathophysiology of chronic stable angina. In: Fuster V, Topol E, Nabel E. Atherothrombosis and coronary artery disease. 2a. ed. Philadelphia: Lippincott Williams & Wilkins, 2005: 1301-2.
(3) Gersh B, Braunwald E, Bonow R. Enfermedad coronaria crónica estable. In: Braunwald E, Zipes D, Libby P. Braunwald’s Cardiología. 6a. ed. Madrid: Marbán 2004: 1553-665.
(4) Fox K, Garcia M, Ardissino D, Buszman P, Camici P, Crea F, et al. Guidelines on the management of stable angina pectoris: executive summary: the Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006; 27(11): 1341-81.
(5) Sociedad Uruguaya de Cardiología, Amonte P, coord. Primer Consenso Uruguayo de Dolor Torácico. Montevideo: SUC, 2003: 38 p.
(6) Thomas M. Tratamiento de la isquemia del miocardio. In: Goodman Gilman A, Goodman, L. Las bases farmacológicas de la terapéutica. 11a. ed. Colombia: McGraw-Hill Interamericana, 2007: 823-44.
(7) Lee L, Horowitz J, Frenneaux M. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment. Eur Heart J 2004; 25: 634-41.
(8) Schofield R, Hill J. Role of metabolically active drugs in the management of ischemic heart disease. Am J Cardiovasc Drugs 2001; 1(1): 23-35.
(9) EMEA. Medical Information System - Pharmaceutical Information. Disponible en: http://www.emea.info (Consulta: 10 de agosto de 2007).
(10) Jackson G. A metabolic approach to the management of ischemic heart disease. Clinical benefits with trimetazidine. Am J Cardiovasc Drugs 2003; 3 Suppl. 1: 27-33.
(11) Kantor P, Lucien A, Kozak R, Lopaschuk G. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2000; 86: 580-8.
(12) Szwed H, Sadowski Z, Elikowski W, Koronkiewicz A, Mamcarz A, Orszulak W, et al. Combination treatment in stable effort angina using trimetazidine and metoprolol. Results of a randomized, double-blind, multicentre study (TRIMPOL II). Eur Heart J 2001; 22: 2267-74.
(13) Levy S. Combination therapy of trimetazidine with diltiazem in patients with coronary artery disease. Group of South of France Investigators. Am J Cardiol 1995; 76(6): 12B-16B.
(14) Hanania G, Haiat R, Olive T, Maalouf B, Michel D, Martelet M, et al. Coronary artery disease observed in general hospitals: ETTIC study. Comparison between trimetazidine and mononitrate isosorbide for patients receiving betablockers. Ann Cardiol Angeiol 2002; 51(5): 268-74.
(15) Marzilli M, Klein W. Efficacy and tolerability of trimetazidine in stable angina: a meta-analysis of randomized, double-blind, controlled trials. Coron Artery Dis 2003; 14(2): 171-9.
(16) Ciapponi A, Pizzarro R, Harrison J. Trimetazidine for stable angina. Cochrane Database Syst Rev [base de datos en Internet]. 2005; CD003614.
(17) Sellier P, Broustet J. Assessment of anti-ischemic and antianginal effect at trough plasma concentration and safety of trimetazidine MR 35 mg in patients with stable angina pectoris: a multicenter, double-blind, placebo-controlled study. Am J Cardiovasc Drugs 2003; 3(5): 361-9.
(18) Chazov E, Lepakchin V, Zharova E, Fitilev S, Levin A, Rumiantzeva E, et al. Trimetazidine in angina combination therapy–the TACT study: trimetazidine versus conventional treatment in patients with stable angina pectoris in a randomized, placebo-controlled, multicenter study. Am J Ther 2005; 12(1): 35-42.
(19) Fabiani J, Ponzio O, Emerit I, Massonet-Castel S, Paris M, Chevalier P, et al. Cardioprotective effect of trimetazidine during coronary artery graft surgery. J Cardiovasc Surgery (Torino) 1992; 33(4): 486-91.
(20) Kolbel F, Bada V. Trimetazidine in geriatric patients with stable angina pectoris: the TIGER study. Int J Clin Pract 2003; 57(10): 867-70.
(21) Marti Massó J. Parkinsonismo por trimetazidina. Neurología 2004; 19: 392-5.
(22) Morillas P, Hernández A, Pallarés V, Bertomeu V, Roldán F, Capdevilla C, et al. Utilidad de la trimetazidina en la lesión por isquemia-reperfusión. Estudio experimental en un modelo canino de aturdimiento miocárdico. Arch Cardiol Mex 2004; 74(4): 262-70.
(23) Ruiz-Meana M. Trimetazidina, estrés oxidativo y daño celular durante la reperfusión miocárdica. Rev Esp Cardiol 2005; 58(8): 895-7.
(24) Pérez Fernández N, Vázquez de la Iglesia F. Tratamiento médico del vértigo. Rev Med Univ Navarra 2003; 47(4): 60-3.
(25) Alacio Casero J, Ortega del Álamo P. Efectividad de trimetazidina en pacientes con alteraciones del equilibrio. Estudio prospectivo multicéntrico. ORL-DIPS 2003; 30(4): 184-92.
(26) Ortín Castaño A, Otero M. Acontecimientos adversos por medicamentos en pacientes ambulatorios como motivo de primera consulta a neurología. Neurología 2006; 21(5): 232-8.
(27) Parkinsonismo asociado a trimetazidina. Bol Tarjeta Amarilla 2006: 2-3.
(28) Rosano G, Vitale C, Sposato B, Mercuro G, Fini M. Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double–blind placebo-controlled study. Cardiovasc Diabetol 2003; 2: 16.
(29) Marzilli M, Affinito S. Meeting the challenge of chronic ischaemic heart disease with trimetazidine. Coron Artery Dis 2005; 16: S23-7.

Effects of trimetazidine in treating stable angina pectoris

Abstract

References

Follow on Twitter